Successful treatment of coccidioidal meningitis with voriconazole

被引:72
作者
Cortez, KJ
Walsh, TJ
Bennett, JE
机构
[1] NIAID, Clin Mycol Sect, Clin Invest Lab, NIH, Bethesda, MD 20892 USA
[2] NCI, Immunocompromised Host Sect, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1086/375235
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A previously healthy 47-year-old man with coccidioidal meningitis had fluconazole treatment failure and developed severe symptoms, multiple cranial nerve palsies, and brainstem inflammation visible on magnetic resonance imaging (MRI). High-dose voriconazole therapy resulted in gradual resolution of almost all signs and symptoms, normalization of cerebrospinal fluid, and clearing of brain-stem edema seen on MRI. The patient had photosensitivity after 10 weeks of treatment, but this improved when the voriconazole dose was lowered. Continuous voriconazole therapy kept coccidioidal meningitis in complete remission in this patient for 12 years.
引用
收藏
页码:1619 / 1622
页数:4
相关论文
共 9 条
  • [1] Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole
    Denning, DW
    Griffiths, CEM
    [J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2001, 26 (08) : 648 - 653
  • [2] DRUTZ DJ, 1978, AM REV RESPIR DIS, V117, P727
  • [3] Erly WK, 1999, AM J NEURORADIOL, V20, P509
  • [4] Practice guidelines for the treatment of coccidioidomycosis
    Galgiani, JN
    Ampel, NM
    Catanzaro, A
    Johnson, RH
    Stevens, DA
    Williams, PL
    [J]. CLINICAL INFECTIOUS DISEASES, 2000, 30 (04) : 658 - 661
  • [5] FLUCONAZOLE THERAPY FOR COCCIDIOIDAL MENINGITIS
    GALGIANI, JN
    CATANZARO, A
    CLOUD, GA
    HIGGS, J
    FRIEDMAN, BA
    LARSEN, RA
    GRAYBILL, JR
    [J]. ANNALS OF INTERNAL MEDICINE, 1993, 119 (01) : 28 - 35
  • [6] Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens
    Purkins, L
    Wood, N
    Ghahramani, P
    Greenhalgh, K
    Allen, MJ
    Kleinermans, D
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) : 2546 - 2553
  • [7] Schwartz S, 1997, BRIT J HAEMATOL, V97, P663, DOI 10.1046/j.1365-2141.1997.972911.x
  • [8] VANWAUWE JP, 1988, J PHARMACOL EXP THER, V245, P718
  • [9] WROBEL CJ, 1992, AM J NEURORADIOL, V13, P1241